Letters and Statements

DLC and DPAC Applaud Senate Appropriations Committee for Acting to Protect Access to Lifesaving Diabetes Technology

DLC and DPAC Applaud Senate Appropriations Committee for Acting to Protect Access to Lifesaving Diabetes Technology


WASHINGTON, D.C., November 17, 2026

The Diabetes Patient Advocacy Coalition (DPAC) and Diabetes Leadership Council (DLC) applaud the Senate Appropriations Committee for taking an important step in protecting access to lifesaving technology for people with diabetes. On Monday, the committee posted its draft fiscal year (FY) 2027 Labor, HHS, Education Appropriations bill. The report accompanying the bill directs the Centers for Medicare and Medicaid Services (CMS) to ensure Medicare beneficiaries with diabetes have reliable access to lifesaving diabetes technology.

In December 2025, despite significant concerns raised by thousands of people with diabetes, DLC, DPAC and other stakeholders, CMS finalized a policy that would include continuous glucose monitors (CGMs) and insulin pumps in the Medicare Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) Competitive Bidding Program. DLC and DPAC remain concerned that this policy will create unnecessary and potentially dangerous disruptions in access to the technologies that people with diabetes rely on every day to administer insulin and manage their blood glucose levels.

DLC and DPAC support efforts to ensure Medicare coverage policies are aligned with current clinical standards of care while safeguarding taxpayer resources. We are encouraged that the Senate Appropriations Committee is sending a strong message to CMS to prioritize patients’ access to medically appropriate diabetes technologies. This direction, along with the language included in the House version released in June, underscores the importance of closely examining the impact of CMS’s policy changes on patient access.

DLC and DPAC look forward to continuing to work with Congress and CMS to ensure that Medicare beneficiaries maintain access to the diabetes technologies that are essential to their health, safety, and quality of life.

PDF
Back to news

DLC and DPAC Applaud Senate Appropriations Committee for Acting to Protect Access to Lifesaving Diabetes Technology


WASHINGTON, D.C., November 17, 2026

The Diabetes Patient Advocacy Coalition (DPAC) and Diabetes Leadership Council (DLC) applaud the Senate Appropriations Committee for taking an important step in protecting access to lifesaving technology for people with diabetes. On Monday, the committee posted its draft fiscal year (FY) 2027 Labor, HHS, Education Appropriations bill. The report accompanying the bill directs the Centers for Medicare and Medicaid Services (CMS) to ensure Medicare beneficiaries with diabetes have reliable access to lifesaving diabetes technology.

In December 2025, despite significant concerns raised by thousands of people with diabetes, DLC, DPAC and other stakeholders, CMS finalized a policy that would include continuous glucose monitors (CGMs) and insulin pumps in the Medicare Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) Competitive Bidding Program. DLC and DPAC remain concerned that this policy will create unnecessary and potentially dangerous disruptions in access to the technologies that people with diabetes rely on every day to administer insulin and manage their blood glucose levels.

DLC and DPAC support efforts to ensure Medicare coverage policies are aligned with current clinical standards of care while safeguarding taxpayer resources. We are encouraged that the Senate Appropriations Committee is sending a strong message to CMS to prioritize patients’ access to medically appropriate diabetes technologies. This direction, along with the language included in the House version released in June, underscores the importance of closely examining the impact of CMS’s policy changes on patient access.

DLC and DPAC look forward to continuing to work with Congress and CMS to ensure that Medicare beneficiaries maintain access to the diabetes technologies that are essential to their health, safety, and quality of life.

Download PDF